Pharmacogenomics is increasingly moving into mainstream clinical practice. Careful
consideration must be paid to inclusion of diverse populations in research, translation and …

There has been a rapid increase in human genome sequencing in the past two decades,
resulting in the identification of millions of previously unknown genetic variants. However …

Adverse drug events (ADEs) account for a significant mortality, morbidity, and cost burden.
Pharmacogenetic testing has the potential to reduce ADEs and inefficacy. The objective of …

Background: Due to racial, cultural, and linguistic marginalization, some populations
experience disproportionate barriers to genetic testing in both clinical and research settings …

Since the publication of the Human Genome Project, genetic information has been used as
an accepted, evidence‐based biomarker to optimize patient care through the delivery of …

Despite the evidence that complicated rheumatic diseases are more prevalent and severe in
ethnic minorities, rheumatology research is afflicted with inadequate patient representation …

While rural–urban cancer disparities persist, the research building capacity between rural
communities and high-quality cancer centers remains limited. Thus, we describe how a …

My first aim identified enrollment patterns and variables that predict enrollment in a diverse
underserved population and evaluated barriers to enrollment. We analyzed data from the …